MERS-CoV spike protein: Targets for vaccines and therapeutics

The disease outbreak caused by Middle East respiratory syndrome coronavirus (MERS-CoV) is still ongoing in the Middle East. Over 1700 people have been infected since it was first reported in September 2012. Despite great efforts, licensed vaccines or therapeutics against MERS-CoV remain unavailable....

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Qihui, Wong, Gary, Lu, Guangwen, Yan, Jinghua, Gao, George F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7113765/
https://www.ncbi.nlm.nih.gov/pubmed/27468951
http://dx.doi.org/10.1016/j.antiviral.2016.07.015
_version_ 1783513742483390464
author Wang, Qihui
Wong, Gary
Lu, Guangwen
Yan, Jinghua
Gao, George F.
author_facet Wang, Qihui
Wong, Gary
Lu, Guangwen
Yan, Jinghua
Gao, George F.
author_sort Wang, Qihui
collection PubMed
description The disease outbreak caused by Middle East respiratory syndrome coronavirus (MERS-CoV) is still ongoing in the Middle East. Over 1700 people have been infected since it was first reported in September 2012. Despite great efforts, licensed vaccines or therapeutics against MERS-CoV remain unavailable. The MERS-CoV spike (S) protein is an important viral antigen known to mediate host-receptor binding and virus entry, as well as induce robust humoral and cell-mediated responses in humans during infection. In this review, we highlight the importance of the S protein in the MERS-CoV life cycle, summarize recent advances in the development of vaccines and therapeutics based on the S protein, and discuss strategies that can be explored to develop new medical countermeasures against MERS-CoV.
format Online
Article
Text
id pubmed-7113765
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-71137652020-04-02 MERS-CoV spike protein: Targets for vaccines and therapeutics Wang, Qihui Wong, Gary Lu, Guangwen Yan, Jinghua Gao, George F. Antiviral Res Article The disease outbreak caused by Middle East respiratory syndrome coronavirus (MERS-CoV) is still ongoing in the Middle East. Over 1700 people have been infected since it was first reported in September 2012. Despite great efforts, licensed vaccines or therapeutics against MERS-CoV remain unavailable. The MERS-CoV spike (S) protein is an important viral antigen known to mediate host-receptor binding and virus entry, as well as induce robust humoral and cell-mediated responses in humans during infection. In this review, we highlight the importance of the S protein in the MERS-CoV life cycle, summarize recent advances in the development of vaccines and therapeutics based on the S protein, and discuss strategies that can be explored to develop new medical countermeasures against MERS-CoV. Elsevier B.V. 2016-09 2016-07-26 /pmc/articles/PMC7113765/ /pubmed/27468951 http://dx.doi.org/10.1016/j.antiviral.2016.07.015 Text en © 2016 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Wang, Qihui
Wong, Gary
Lu, Guangwen
Yan, Jinghua
Gao, George F.
MERS-CoV spike protein: Targets for vaccines and therapeutics
title MERS-CoV spike protein: Targets for vaccines and therapeutics
title_full MERS-CoV spike protein: Targets for vaccines and therapeutics
title_fullStr MERS-CoV spike protein: Targets for vaccines and therapeutics
title_full_unstemmed MERS-CoV spike protein: Targets for vaccines and therapeutics
title_short MERS-CoV spike protein: Targets for vaccines and therapeutics
title_sort mers-cov spike protein: targets for vaccines and therapeutics
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7113765/
https://www.ncbi.nlm.nih.gov/pubmed/27468951
http://dx.doi.org/10.1016/j.antiviral.2016.07.015
work_keys_str_mv AT wangqihui merscovspikeproteintargetsforvaccinesandtherapeutics
AT wonggary merscovspikeproteintargetsforvaccinesandtherapeutics
AT luguangwen merscovspikeproteintargetsforvaccinesandtherapeutics
AT yanjinghua merscovspikeproteintargetsforvaccinesandtherapeutics
AT gaogeorgef merscovspikeproteintargetsforvaccinesandtherapeutics

Ejemplares similares